A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL IX
- Sponsors Novo Nordisk
Most Recent Events
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 05 Oct 2018 Results investigating the safety and efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes